Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, Elicio Therapeutics is raising $30,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Robert Connelly played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Elicio Therapeutics

Elicio is engineering potent immuno-therapies for an array of aggressive cancers. Elicio, based in Cambridge MA, is committed to transforming the lives of patients and their families by re-engineering the body’s immune response to defeat cancer. Elicio was founded to expand and apply the ground-breaking Amphiphile technology invented and developed by Darrell Irvine Ph.D. Elicio’s lead Amphiphile vaccine targeting pancreatic cancer and colorectal cancer will begin initial patient studies in 2020.

To learn more about Elicio Therapeutics, visit http://elicio.com/

Contact:
Robert Connelly, Chief Executive Officer
857-209-0056
https://www.linkedin.com/in/robert-connelly-b0445516/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved